Nantes, France, January 21, 2026 – 6pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173;
Mnemo: OSE), today acknowledges the announcement by its partner Veloxis Pharmaceuticals, Inc.
that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to
pegrizeprument (VEL-101) for the prevention of organ rejection in patients undergoing liver
transplantation